Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Really focus on Your Dental Inserts for Durable Outcomes - 2Gauging the Upsides and downsides of Visas: A Complete Aide
- 3‘Wicked: For Good’ streaming release — How to watch the sequel starring Ariana Grande and Cynthia Erivo
- 46 Tire Brands Reasonable for Seniors
- 5South Korea launches Earth-observation satellite on homegrown Nuri rocket
- Exploring the Market: Unsold Rams May Be Less expensive Than You Naturally suspect
- Unsold Rams May Be Less expensive Than You Suspect
- What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- 'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- Our 10 favorite Space.com reader astronomy photos of 2025
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- Which game do you cherish observing live? Vote!
